TITLE

Quark Signs Research Pact With Shionogi

PUB. DATE
March 2000
SOURCE
Worldwide Biotech;Mar2000, Vol. 12 Issue 3, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the research and license agreement signed by Quark Biotech Inc. and Shionogi & Co. to discover and analyze genes associated with osteoarthritis.
ACCESSION #
2889682

 

Related Articles

  • Pfizer licenses gene for possible AMD therapy.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p8 

    The article reports on the acquisition of Pfizer Inc. of the worldwide license to a novel human gene with Quark Biotech Inc. in the U.S. Under the deal, the former will develop the gene called RTP-801, and molecules that modify it that could have the potential to treat neovascular age-related...

  • BioCryst Monetizes Peramivir Payments in $30M Financing.  // Bioworld Week;3/14/2011, Vol. 19 Issue 11, p5 

    The article offers information on the license agreement between BioCryst Pharmaceuticals Inc. and Shionogi & Co. Ltd. for peramivir (Rapiacta), drug used to treat influenza.

  • $125M: Quatrx Licenses Ospemifene to Shionogi.  // Bioworld Week;3/8/2010, Vol. 18 Issue 10, p4 

    The article reports on the licensing agreement between Ann Arbor, Michigan-based Quatrx Pharmaceuticals Co. and Japan's Shionogi & Co. Ltd. for Quatrx's ospemifene, late stage women's health product.

  • BioCryst Getting $14M Up Front From Japanese Peramivir Partner. Boggs, Jennifer // BioWorld Today;2/7/2007, Vol. 18 Issue 45, p1 

    The article reports that BioCryst Pharmaceuticals Inc. has licensed Japanese rights to the influenza antiviral peramivir in a potential $130 million deal. The deal includes a $14 million up-front payment from Osaka, Japan-based Shionogi & Co. Ltd., which receives rights in Japan to create...

  • Shionogi enters into license agreement with Janssen for Alzheimer's treatment.  // PharmaWatch: CNS;Dec2012, Vol. 11 Issue 12, p12 

    The article reports on a license agreement signed by Japan-based Shionogi & Co., Ltd. with Janssen Pharmaceuticals, Inc. The license agreement covers research collaboration and the development and commercialization of oral beta-secretase, or BACE, inhibitors for Alzheimer's disease treatment....

  • Quark Biotech earns patent.  // Crain's Cleveland Business;8/5/2002, Vol. 23 Issue 31, p12 

    Reports the patent given to Quark Biotech Inc. for developing a method to identify genes encoding secreted and membranal proteins in Cleveland, Ohio.

  • Biotech firm may build close to Clinic. Thompson, Chris // Crain's Cleveland Business;01/01/2001, Vol. 22 Issue 1, p3 

    Reports on the possibility that biotechnology firm Quark Biotech Inc. will construct a building near the Cleveland Clinic's campus in Cleveland, Ohio. Finalization of plans to transfer to Cleveland; Reasons of Quark for choosing a location near Cleveland Clinic's campus; Plans of Cleveland...

  • Shionogi and Eli Lilly Japan win approval for additional indication of DNP drug.  // PharmaWatch: CNS;Apr2012, Vol. 11 Issue 4, p14 

    The article reports that Shionogi & Co. Ltd. and Eli Lilly Japan K.K. have received an approval for an additional indication of a diabetic neuropathic drug (DNP) Cymbalta capsule 20 milligram (mg) and Cymbalta capsule 30mg in Japan.

  • Giveaways can't assure our tech future. Thompson, Chris // Crain's Cleveland Business;9/29/2003, Vol. 24 Issue 39, p10 

    Government shouldn't give money to private business. That is the most important lesson of many that should be learned by the announcement that Quark Biotech Inc. is leaving Cleveland for California. Back in 2001, Quark moved to Cleveland from Chicago to follow a researcher, Andrei Gudkov, who...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics